Rokit America

What Rokit America does

ROKIT America, Inc. is a Delaware-incorporated biotechnology company headquartered in Los Angeles, founded in 2012 with 51–100 employees. The company operates two distinct product lines. The first is a consumer-facing anti-aging dietary supplement business built around NMN (nicotinamide mononucleotide) and Fisetin products marketed for cellular health and detoxification, scaled primarily through the Coupang marketplace in South Korea — which accounts for 53% of revenue — alongside direct-to-consumer sales via the company website. The second is an investigational AI-guided 3D bioprinting platform targeting organ and tissue regeneration across skin, cartilage, and kidney applications; these products are explicitly described as unproven and not FDA-approved, with 70% of planned IPO net proceeds allocated to their development.

The business model is dual-track. On the supplement side, revenue is generated via one-time product sales through marketplace and DTC channels, with FY2025 revenue of $7.4M representing 140% year-over-year growth and Coupang product sales growing 328% year-over-year off a small base. The go-to-market is product-led through localized SKUs, supplemented by marketplace-channel distribution. On the regenerative medicine side, there is no current revenue; the company is positioning for an enterprise/clinical sales motion funded by IPO proceeds. The primary customer segment today is health-conscious consumers and biohackers; a future clinical segment targeting skin, cartilage, and kidney regeneration is the intended but unrealized audience.

FY2025 revenue of $7.4M is concentrated in South Korea through a single channel partner, and customer acquisition costs have doubled to 28% of revenue, indicating rising growth friction. The company filed an S-1 for an IPO on Nasdaq under symbol RKAM in April 2026, targeting $21.19M–$25M at an enterprise valuation of approximately $240M — a multiple noted by third-party analysts as substantially above comparable supplement peers.

Name

Rokit America

Legal name

ROKIT America, Inc.

Website

https://rokitamerica.com

Company type

Private

Founded year

2012

Operating status

Ipo

Headcount range

51–100 employees

Short description

ROKIT America is a biotechnology company selling NMN and Fisetin anti-aging dietary supplements through the Coupang South Korea marketplace and its own website, while developing an investigational AI-guided 3D bioprinting platform for skin, cartilage, and kidney organ regeneration.

Ownership category

akta.pro rank

Product category

Nutraceuticals and biotechnology

NAICS

Food (Health) Supplement Retailers (456191), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Healthy Aging & Cognitive Support Supplements (CRADAGAM)

akta.pro secondary industry

Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• NMN dietary supplements
• Anti-aging supplements
• Bioprinting organ regeneration
• Reconstructive biotechnology
• Longevity healthspan

Headquarters

HQ city

Northridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Technology or R&D, Operations, Personnel

Revenue model

1. NMN-Based Dietary Supplements: Revenue primarily derived from anti-aging NMN-based supplements sold primarily in South Korea (53% of sales), with additional products including Fisetin supplements marketed for cellular health and detoxification. Product sales on Coupang grew 328% year-over-year in 2025. Company scaled from one product to five localized SKUs.
2. Organ Regeneration Products (Pipeline): Future revenue stream from developing unproven organ regeneration products for skin, cartilage, and kidney regeneration. Currently investigational and not FDA-approved. Company plans to allocate 70% of IPO net proceeds to develop these products.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels2 records

Core offering

ROKIT America sells NMN-based dietary supplements (including Fisetin) for cellular health, detoxification, and longevity, distributed as five localized SKUs primarily through Coupang in South Korea and its own DTC website. The company is also developing an AI-guided 3D bioprinting organ regeneration platform for skin, cartilage, and kidney tissue restoration, although products remain investigational and unproven.

Product overview

ROKIT America operates as a reconstructive biotechnology company offering two main product lines: (1) NMN-based dietary supplements for anti-aging and cellular health, including Fisetin supplements and the planned Biohacker series, and (2) an AI-guided 3D bioprinting organ regeneration platform targeting skin, cartilage, and kidney regeneration. The organ regeneration products are investigational and unproven, with the company allocating IPO proceeds toward their development.

Differentiator

Problem solved

Functional benefit

Brands

• Biohacker Series: Product line under development for the second half of 2025, including new supplements for cellular health and detoxification.

Products and services

• NMN-Based Dietary Supplements Anti-aging dietary supplements containing NMN (Nicotinamide Mononucleotide) marketed for cellular health, longevity support, and healthspan extension. Sold to health-conscious consumers and biohackers globally via Coupang and the company's DTC website.
• Fisetin Supplements Fisetin-based dietary supplements marketed for cellular health and detoxification, sold alongside the NMN supplements through the same channels.

Quantifiable outcome

• 140% year-over-year revenue growth in FY2025
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• CoupangcoreChannel Partner/ Reseller/ Distributor · 11 July 2025ROKIT America expanded into South Korea through partnership with e-commerce platform Coupang. Product sales on Coupang grew 328% year-over-year in 2025, with NMN and Fisetin supplements marketed for cellular health and detoxification. Company scaled from one product to five localized SKUs on the platform, representing 53% of company revenue and planned to launch three new products under Biohacker series in H2 2025.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rokithealthcare

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rokit America